By Karen Roman
Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it presented new research findings at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders taking place March 17-21, 2026, in Copenhagen and online.
The data displays efforts to advance Alzheimer’s treatment through three key areas which include developing enhanced brain delivery methods and evaluating novel biomarker approaches, among others, it stated.
“These presentations collectively demonstrate how we’re addressing the key challenges that have limited success in Alzheimer’s drug development – delivery, measurement, timing, and selectivity,” said Jim Doherty, Acumen President and Chief Development Officer.
The data posters presented will be available after each poster session concludes on the company’s website at: https://acumenpharm.com/publications/.
READ MORE
IPO Edge NYSE Firesides Scheduled for March 20 & June 2
Register for our weekly newsletter HERE
Contact:
Click HERE to follow us on LinkedIn
